NAN logo

Nanosonics Limited Stock Price

ASX:NAN Community·AU$1.3b Market Cap
  • 3 Narratives written by author
  • 1 Comments on narratives written by author
  • 41 Fair Values set on narratives written by author

NAN Share Price Performance

AU$4.44
0.74 (20.00%)
28.2% undervalued intrinsic discount
AU$6.18
Fair Value
AU$4.44
0.74 (20.00%)
26.0% undervalued intrinsic discount
AU$6.00
Fair Value
Price AU$4.44
AnalystHighTarget AU$6.00
AnalystConsensusTarget AU$4.63
AnalystLowTarget AU$3.75

NAN Community Narratives

AnalystHighTarget·Updated
Fair Value AU$6.18 28.2% undervalued intrinsic discount

Rising Global Aging And Regulatory Demands Will Accelerate Automated Disinfection

1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value AU$4.75 6.5% undervalued intrinsic discount

Automated Disinfection Solutions Will Transform Hospital Safety Worldwide

1users have liked this narrative
1users have commented on this narrative
23users have followed this narrative
AnalystLowTarget·Updated
Fair Value AU$3.9 13.8% overvalued intrinsic discount

Rising Hospital Cost Containment And Tech Obsolescence Will Erode Profitability

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Recent NAN News & Updates

Nanosonics Limited's (ASX:NAN) Intrinsic Value Is Potentially 31% Above Its Share Price

Jul 04
Nanosonics Limited's (ASX:NAN) Intrinsic Value Is Potentially 31% Above Its Share Price

Nanosonics (ASX:NAN) Ticks All The Boxes When It Comes To Earnings Growth

Mar 30
Nanosonics (ASX:NAN) Ticks All The Boxes When It Comes To Earnings Growth

We Think Nanosonics' (ASX:NAN) Solid Earnings Are Understated

Feb 26
We Think Nanosonics' (ASX:NAN) Solid Earnings Are Understated

Nanosonics Limited's (ASX:NAN) Shares Climb 26% But Its Business Is Yet to Catch Up

Feb 24
Nanosonics Limited's (ASX:NAN) Shares Climb 26% But Its Business Is Yet to Catch Up
User avatar

CORIS FDA Filing Will Set New Standard In Endoscopy Reprocessing

Strategic growth in high-margin recurring revenue and further North American market penetration in the trophon business suggest enhanced revenue and net margins.

Nanosonics Limited Key Details

AU$198.6m

Revenue

AU$43.3m

Cost of Revenue

AU$155.4m

Gross Profit

AU$134.7m

Other Expenses

AU$20.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.068
Gross Margin
78.22%
Net Profit Margin
10.41%
Debt/Equity Ratio
0%

Nanosonics Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with solid track record.

0 Risks
2 Rewards

About NAN

Founded
2000
Employees
470
CEO
Michael Kavanagh
WebsiteView website
www.nanosonics.com.au

Nanosonics Limited operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. The company manufactures and distributes trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. It also provides trophon2 a device with an enhanced design and new functionality, including AcuTrace TM for audit-ready digital record-keeping and capabilities to connect trophon 2 with hospital IT systems; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Australian Market Performance

  • 7 Days: 2.3%
  • 3 Months: 5.3%
  • 1 Year: 10.1%
  • Year to Date: 9.7%
The market has climbed 2.3% in the last 7 days, lead by the Financials sector with a gain of 2.9%. As for the past 12 months, the market is up 10%. Looking forward, earnings are forecast to grow by 11% annually. Market details ›